razoxane has been researched along with Central Nervous System Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dejligbjerg, M; Hofland, KF; Jensen, LH; Jensen, PB; Kristjansen, PE; Rengtved, P; Sehested, M; Thougaard, AV | 1 |
| Holm, B; Jensen, PB; Sehested, M | 1 |
2 other study(ies) available for razoxane and Central Nervous System Neoplasms
| Article | Year |
|---|---|
Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Central Nervous System Neoplasms; Combined Modality Therapy; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Female; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Razoxane; Survival Analysis; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Central Nervous System Neoplasms; DNA Topoisomerases, Type II; Etoposide; Female; Injections, Intraperitoneal; Lethal Dose 50; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Paclitaxel; Razoxane; Structure-Activity Relationship | 1996 |